Serological biomarkers are essential in diagnosing, prognosticating, and managing triple-negative breast cancer (TNBC), a subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.